IDEXX Laboratories, Inc. (BVMF:I1DX34)
Brazil · Delayed Price · Currency is BRL | Market Cap | 225.30B +14.9% |
| Revenue (ttm) | 23.19B +13.1% |
| Net Income | 5.71B +22.4% |
| EPS | 70.92 +25.7% |
| Shares Out | n/a |
| PE Ratio | 39.43 |
| Forward PE | 38.15 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 17 |
| Average Volume | 49 |
| Open | 567.74 |
| Previous Close | 557.48 |
| Day's Range | 567.74 - 567.74 |
| 52-Week Range | 544.00 - 813.60 |
| Beta | 1.72 |
| RSI | 33.33 |
| Earnings Date | May 5, 2026 |
About IDEXX Laboratories
IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally. It operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. The company offers point-of-care diagnostic solutions, blood and urine chemistry, hematology, immunoassay, urinalysis, cytology/morphology, and coagulation analyzers; and SNAP rapid assays test kits. It also provides com... [Read more]
Financial Performance
In 2025, IDEXX Laboratories's revenue was $4.30 billion, an increase of 10.42% compared to the previous year's $3.90 billion. Earnings were $1.06 billion, an increase of 19.33%.
Financial numbers in USD Financial StatementsNews
Idexx Laboratories price target lowered to $660 from $790 at BofA
BofA lowered the firm’s price target on Idexx Laboratories (IDXX) to $660 from $790 and keeps a Neutral rating on the shares. The firm sees today’s Q1 beat as “demonstrating
IDEXX Laboratories Earnings Call Transcript: Q1 2026
Q1 2026 saw 14% reported and 11% organic revenue growth, with strong gains in CAG Diagnostics, premium instrument placements, and international markets. Full-year guidance was raised for revenue, EPS, and operating margin, supported by innovation and robust customer retention.
Idexx Laboratories reports Q1 EPS $3.47, consensus $3.41
Reports Q1 revenue $1.14B, consensus $1.11B. “Excellent commercial execution delivered exceptional first quarter results and positions IDEXX for continued strength through 2026,” said Jay Mazelsky, Pr...
Idexx Laboratories raises FY26 EPS view to $14.45-$14.90 from $14.29-$14.80
FY26 consensus $14.51. Raises FY26 reported revenue growth view to 8.6%-10.6% and CAG Diagnostics recurring revenue reported growth of 9.6%-11.6%, with projected 2026 organic revenue growth of 7.7%-9....
IDEXX Laboratories Announces First Quarter Results
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced first quarter results. First Quarter Results The Company repor...
Idexx Laboratories price target lowered to $640 from $730 at UBS
UBS analyst Andrea Alfonso lowered the firm’s price target on Idexx Laboratories (IDXX) to $640 from $730 and keeps a Neutral rating on the shares. The Q1 earnings outlook is
University of New England launches new Institute of Public and Planetary Health in honor of philanthropist and IDEXX Founder David Evans Shaw
A $5 million gift from the storied entrepreneur, activist, and impact investor will advance the University of New England's work at the intersection of environmental and human health while boosting Ma...
Idexx Laboratories initiated with a Neutral at Citi
Citi analyst Daniel Grosslight initiated coverage of Idexx Laboratories (IDXX) with a Neutral rating and $650 price target The firm launched the animal health and dental sectors with a “cautiously
IDEXX Laboratories to Release 2026 First Quarter Financial Results
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2026 first quarter financial results for Tues...
Idexx Laboratories announces Idexx Cancer Dx Panel availability in the UK
Idexx Laboratories (IDXX) announced the availability of the Idexx Cancer Dx Panel in the United Kingdom, beginning with early detection of lymphoma in at-risk dogs. Published first on TheFly –
IDEXX Announces UK Availability of Cancer Dx Panel for Early Detection of Canine Lymphoma
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Cancer Dx Panel with canine lymphoma detection helps clinicians investigate sooner and plan next steps with confidence.
Idexx Laboratories price target lowered to $675 from $775 at Stifel
Stifel analyst Jonathan Block lowered the firm’s price target on Idexx Laboratories (IDXX) to $675 from $775 and keeps a Buy rating on the shares. The firm continues to view
Idexx Laboratories management to meet with Piper Sandler
Meeting to be held in Boston on April 1 hosted by Piper Sandler. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See
IDEXX Laboratories Transcript: 47th Annual Raymond James Institutional Investor Conference
A robust innovation-driven strategy is fueling double-digit growth in veterinary diagnostics, supported by expanding international markets, increased pet longevity, and accelerated investment in new platforms and oncology solutions. Long-term targets include 10%+ revenue growth and 15%+ EPS growth.
IDEXX Laboratories Transcript: BofA Securities Animal Health Summit
Double-digit organic revenue growth and record instrument placements were achieved in 2025, driven by innovation in diagnostic platforms like inVue Dx and Cancer Dx. Despite sector headwinds, recurring revenue and margin expansion are expected to continue in 2026, supported by a stable leadership team.
IDEXX Laboratories to Present at Two Institutional Investor Conferences
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, will participate in two upcoming conferences: Thursday, February 26, 9:55 am –...
Idexx Laboratories price target lowered to $750 from $775 at Piper Sandler
Piper Sandler lowered the firm’s price target on Idexx Laboratories (IDXX) to $750 from $775 and keeps a Neutral rating on the shares following quarterly results. The firm says its
Idexx Laboratories price target lowered to $800 from $850 at Barclays
Barclays analyst Glen Santangelo lowered the firm’s price target on Idexx Laboratories (IDXX) to $800 from $850 and keeps an Overweight rating on the shares. The firm updated the company’s
Idexx Laboratories price target lowered to $730 from $750 at UBS
UBS analyst Andrea Alfonso lowered the firm’s price target on Idexx Laboratories (IDXX) to $730 from $750 and keeps a Neutral rating on the shares. The print showed mixed signals,
Idexx Laboratories price target lowered to $800 from $830 at BTIG
BTIG lowered the firm’s price target on Idexx Laboratories (IDXX) to $800 from $830 and keeps a Buy rating on the shares. The company delivered a good Q4 beat on
IDEXX Laboratories Earnings Call Transcript: Q4 2025
Q4 and full-year 2025 saw double-digit organic revenue growth, record instrument placements, and strong EPS gains, driven by innovation and international expansion. 2026 guidance anticipates continued robust growth, margin improvement, and capital returns, despite sector headwinds.
IDEXX forecasts 2026 revenue, profit above estimates on strong demand for pet diagnostics
Animal diagnostics maker IDEXX Laboratories on Monday forecast 2026 revenue and profit above Wall Street estimates, betting that resilient demand at veterinary clinics and higher testing per visit wil...
Options Volatility and Implied Earnings Moves Today, February 02, 2026
Today, several major companies are expected to report earnings: Alliance Resource (ARLP), Aptiv (APTV), Idexx Laboratories (IDXX), NXP Semiconductors (NXPI), Simon Property (SPG), Teradyne (TER), Two ...
Idexx Laboratories reports Q4 EPS $3.08, consensus $2.94
Reports Q4 revenue $1.09B, consensus $1.07B. “IDEXX delivered a strong finish to 2025, supported by consistently high levels of execution by IDEXX teams around the world,” said Jay Mazelsky, President
Idexx Laboratories sees FY26 EPS $14.29-$14.80, consensus $14.45
Sees FY26 revenue $4.632B-$4.72B, consensus $4.66B. The company’s initial 2026 revenue guidance range of $4.632B-$4.72B, or reported growth of 7.6%-9.6% and 7.0%-9.0% on an organic basis, is supported...